| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other expense | -14,702 | -15,886 | -15,453 | -14,781 |
| Net loss and comprehensive loss | -29,973 | -75,810 | -94,316 | -85,577 |
| Net loss per share, basic | -0.41 | -1.05 | -1.31 | -1.32 |
| Net loss per share, diluted | -0.41 | -1.05 | -1.31 | -1.32 |
| Weighted-average shares of common stock outstanding, basic | 73,396,435 | 72,466,203 | 71,969,411 | 64,627,847 |
| Weighted-average shares of common stock outstanding, diluted | 73,396,435 | 72,466,203 | 71,969,411 | 64,627,847 |
Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT)